Description
In this webinar, cardiologist Martha Grogan, MD, and hematologist Prashant Kapoor, MD, provide an overview of amyloidosis, including tests and evaluations, treatment options and how to manage your symptoms. A question and answer session followed the presentation.
Would you like to:
A second SCT is a viable option, especially if the first SCT led to prolonged remission. Typically however, the impact of a second SCT is not as durable as the first. Candidacy for another SCT would have to be assessed. The pros and cons of the other non-SCT options, including bortezomib- based chemo regimens, particularly if not used previously, should be discussed with the physician in detail.
Del 17 p is considered a high risk feature in myeloma. Only nine patients with AL amyloidosis (2%) were identified with a deletion (17p) in a recent retrospective study of 401 patients published by the Mayo Clinic Group. The nine patients with deletion 17p had the highest level of bone marrow plasma cell infiltration. No significant difference in overall survival for the high-risk FISH features could be documented, but the study was limited by very small numbers of high risk abnormalities. In the absence of hard data in AL amyloidosis, I would err on the side of considering del 17p as a high-risk feature. Usually bortezomib-based therapies are considered more effective in patients with del 17p.
Phase 2 is still putting patients on the waiting list.
As far as lichen amyloidosis, we could assist, but it isn’t something we have as a specialty clinic or strong web presence on.
hello, my wife have amyloidosis in the heart, you take egcg and that disrupt fibrills amyloids . Com on to facebook amyloidosis international, i give you the good information. 8 months ago doctors want transplant the heart from my wife from 32 years, im living in belgium and give information. We dont change heart, take egcg and other natural things, that work really.<br />
Best regards <br />
Philippe<br />
<br />
Envoyé de mon iPad